MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

NCT03008187 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: MEN1703

Sponsor

Menarini Group

Collaborators

[object Object]
[object Object]